ECSP105695A - Proceso para la fabricacion de valsartan - Google Patents

Proceso para la fabricacion de valsartan

Info

Publication number
ECSP105695A
ECSP105695A EC2010005695A ECSP105695A ECSP105695A EC SP105695 A ECSP105695 A EC SP105695A EC 2010005695 A EC2010005695 A EC 2010005695A EC SP105695 A ECSP105695 A EC SP105695A EC SP105695 A ECSP105695 A EC SP105695A
Authority
EC
Ecuador
Prior art keywords
valsartan
manufacturing process
angiotensin
receptor antagonist
receptor
Prior art date
Application number
EC2010005695A
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Hans Hirt
Christoph Krell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP105695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP105695A publication Critical patent/ECSP105695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a un proceso para la fabricación de Valsartan, un bloqueador del receptor de angiotensina (ARB; también denominado antagonista del receptor de angiotensina II ó antagonista del receptor AT1), y sales del mismo, a intermediarios novedosos, y a los pasos del proceso.
EC2010005695A 2002-09-23 2010-02-11 Proceso para la fabricacion de valsartan ECSP105695A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222056.4A GB0222056D0 (en) 2002-09-23 2002-09-23 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
ECSP105695A true ECSP105695A (es) 2010-03-31

Family

ID=9944606

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2005005695A ECSP055695A (es) 2002-09-23 2005-03-21 Proceso para la fabricacion de valsartan
EC2010005695A ECSP105695A (es) 2002-09-23 2010-02-11 Proceso para la fabricacion de valsartan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2005005695A ECSP055695A (es) 2002-09-23 2005-03-21 Proceso para la fabricacion de valsartan

Country Status (29)

Country Link
US (3) US20060069268A1 (es)
EP (2) EP1546122B8 (es)
JP (2) JP4787498B2 (es)
KR (2) KR20110015703A (es)
CN (2) CN101153027B (es)
AR (1) AR041360A1 (es)
AU (1) AU2003270241B2 (es)
BR (1) BR0314132A (es)
CA (1) CA2502629A1 (es)
CY (1) CY1107878T1 (es)
DE (1) DE60317690T2 (es)
DK (1) DK1546122T3 (es)
EC (2) ECSP055695A (es)
ES (1) ES2295623T3 (es)
GB (1) GB0222056D0 (es)
IL (1) IL167426A (es)
MX (1) MXPA05003140A (es)
MY (1) MY138618A (es)
NO (2) NO20051970L (es)
NZ (2) NZ538927A (es)
PE (2) PE20050088A1 (es)
PL (1) PL374862A1 (es)
PT (1) PT1546122E (es)
RU (2) RU2412173C2 (es)
SG (1) SG155049A1 (es)
SI (1) SI1546122T1 (es)
TW (2) TWI338003B (es)
WO (1) WO2004026847A1 (es)
ZA (1) ZA200502159B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
ES2238022T3 (es) * 2003-03-17 2008-11-01 Teva Pharmaceutical Industries Ltd. Poliformos de valsartan.
EP1618097A1 (en) 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1661891A1 (en) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto A process for the synthesis of valsartan
GB0514206D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
WO2008004110A2 (en) * 2006-07-03 2008-01-10 Aurobindo Pharma Limited Process for the preparation of the angiotensin ii antagonist valsartan
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2316821A1 (en) 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
MA34580B1 (fr) * 2010-08-03 2013-10-02 Novartis Ag Valsartan hautement cristallin
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN103554047A (zh) * 2013-10-11 2014-02-05 镇江市高等专科学校 制备缬沙坦的方法
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072433A (zh) * 2014-07-16 2014-10-01 南京正大天晴制药有限公司 一种缬沙坦的水解杂质化合物及其制备方法、检测方法和用途
CN104151199A (zh) * 2014-08-13 2014-11-19 苏州卫生职业技术学院 一种缬沙坦的合成方法
CN104844476B (zh) * 2015-04-03 2016-08-24 李凌 一种医药中间体联苯类化合物的合成方法
CN112014479A (zh) * 2019-05-28 2020-12-01 珠海润都制药股份有限公司 一种缬沙坦中正戊酰氯的检测方法
CN116655498B (zh) * 2023-05-24 2025-01-28 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种沙库巴曲中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
FR2688503B1 (fr) * 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (fr) * 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US5412102A (en) * 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
DE69507887T2 (de) * 1994-09-20 1999-06-17 Wakunaga Seiyaku K.K., Osaka Verfahren zur herstellung von n-biphenylmethylthiadiazolin derivaten oder deren salzen sowie dafür benötigte zwischen verbindungen
DE69628175D1 (de) * 1995-06-07 2003-06-18 Wyeth Corp Verfahren zur herstellung von biphenylderivaten
AU7213296A (en) * 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
AR032758A1 (es) * 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
JP4537678B2 (ja) * 2003-09-04 2010-09-01 住友化学株式会社 ２’−（１ｈ−テトラゾール−５−イル）ビフェニル−４−カルボアルデヒド結晶およびその製造方法
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
CN100357279C (zh) 2007-12-26
ZA200502159B (en) 2005-09-21
EP1546122B8 (en) 2008-05-28
US20060069268A1 (en) 2006-03-30
AR041360A1 (es) 2005-05-11
DK1546122T3 (da) 2008-03-03
RU2348619C2 (ru) 2009-03-10
TWI329106B (en) 2010-08-21
CN101153027A (zh) 2008-04-02
TW201016673A (en) 2010-05-01
AU2003270241A1 (en) 2004-04-08
SI1546122T1 (sl) 2008-04-30
RU2412173C2 (ru) 2011-02-20
SG155049A1 (en) 2009-09-30
HK1079771A1 (en) 2006-04-13
KR20050057529A (ko) 2005-06-16
EP1546122B1 (en) 2007-11-21
CA2502629A1 (en) 2004-04-01
ES2295623T3 (es) 2008-04-16
PL374862A1 (en) 2005-11-14
RU2005112444A (ru) 2006-01-20
MXPA05003140A (es) 2005-06-22
TWI338003B (en) 2011-03-01
NZ566863A (en) 2009-08-28
CN1688556A (zh) 2005-10-26
EP1546122A1 (en) 2005-06-29
CY1107878T1 (el) 2013-06-19
PE20091387A1 (es) 2009-10-13
NO20051970L (no) 2005-06-16
IL167426A (en) 2010-11-30
EP1878729A1 (en) 2008-01-16
US20100249429A1 (en) 2010-09-30
DE60317690T2 (de) 2008-10-30
NO20110856L (no) 2005-06-16
CN101153027B (zh) 2010-08-18
PE20050088A1 (es) 2005-02-21
TW200413337A (en) 2004-08-01
GB0222056D0 (en) 2002-10-30
KR20110015703A (ko) 2011-02-16
JP4787498B2 (ja) 2011-10-05
RU2008133680A (ru) 2010-02-27
AU2003270241B2 (en) 2007-08-23
BR0314132A (pt) 2005-06-28
JP2010254709A (ja) 2010-11-11
MY138618A (en) 2009-07-31
PT1546122E (pt) 2008-02-14
ECSP055695A (es) 2005-05-30
NZ538927A (en) 2008-05-30
JP2006502178A (ja) 2006-01-19
US20090111995A1 (en) 2009-04-30
DE60317690D1 (de) 2008-01-03
WO2004026847A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
ECSP105695A (es) Proceso para la fabricacion de valsartan
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
CL2009001063A1 (es) Uso de una combinacion de un compuesto derivado de n-quinoliniloxifenil-n-fenilciclopropanodicarboxamida y un inhibidor de erbb seleccionado entre lapatinib, erlotinib, gefitinib, trastuzumab, cetuximab, para eltratamiento de canceres.
NI200500031A (es) Nuevos procesos para la sintesis de ivabradine y ademas sales que la contienen con un acido aceptable farmaceuticamente.
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
NO20080761L (no) Acykliske Ikur inhibitorer
BR0317139A (pt) Métodos e compostos para produção de inibidores de dipeptidil peptidase iv e seus intermediários
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
CY1109088T1 (el) Μεθοδος για την παρασκευη υποκατεστημενων ενωσεων 3-αρυλο-βουτυλ-αμινης
NO20073875L (no) Krystallformer av 1-klor-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzyl]-benzen, metode for fremstilling samt anvendelse for fremstilling av medikamenter
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
CR10157A (es) Compuestos químicos
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
ECSP066753A (es) Antagonistas del receptor de quimiocina
UA90706C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
NO20075706L (no) Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder
MX351611B (es) Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
MEP15908A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
TW200600494A (en) Bisphenyl compounds useful as vitamin d3 receptor agonists
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
TW200628174A (en) Bilayer tablet
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
EA200870038A1 (ru) Способ получения аминов
EA200901598A1 (ru) Способ получения триазолонов